Description: Oncorus, Inc., a clinical stage biopharmaceutical company, focuses to develop viral immunotherapies for cancer patients. Its lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform that it is in Phase I clinical trial to treat various cancers. The company is also developing ONCR-GBM program for treating brain cancer; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. Oncorus, Inc. has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Home Page: www.oncorus.com
ONCR Technical Analysis
50 Hampshire Street
Cambridge,
MA
02139
United States
Phone:
857 320 6400
Officers
| Name | Title |
|---|---|
| Dr. Mitchell H. Finer Ph.D. | Non-Exec. Chairman |
| Dr. Theodore T. Ashburn M.D., Ph.D. | Pres, CEO & Director |
| Mr. Stephen W. Harbin | COO & Chief of Staff |
| Mr. Richard J. Wanstall M.B.A. | CFO, Chief Accounting Officer & Treasurer |
| Brian J. Shea | Director of Legal Counsel & Corp. Sec. |
| Dr. John Mayer Goldberg M.D. | Chief Medical Officer |
| Chris German | Controller |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.1266 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-10-02 |
| Fiscal Year End: | December |
| Full Time Employees: | 82 |